ALEMBIC | SUVEN LIFE SCIENCES | ALEMBIC/ SUVEN LIFE SCIENCES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 60.4 | -82.0 | - | View Chart |
P/BV | x | 5.2 | 1.3 | 404.3% | View Chart |
Dividend Yield | % | 0.2 | 1.8 | 11.0% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALEMBIC Mar-18 |
SUVEN LIFE SCIENCES Mar-19 |
ALEMBIC/ SUVEN LIFE SCIENCES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 72 | 338 | 21.3% | |
Low | Rs | 34 | 169 | 20.0% | |
Sales per share (Unadj.) | Rs | 4.7 | 52.1 | 9.0% | |
Earnings per share (Unadj.) | Rs | 6.1 | 6.8 | 89.4% | |
Cash flow per share (Unadj.) | Rs | 6.2 | 8.6 | 72.9% | |
Dividends per share (Unadj.) | Rs | 0.20 | 1.50 | 13.3% | |
Dividend yield (eoy) | % | 0.4 | 0.6 | 63.8% | |
Book value per share (Unadj.) | Rs | 40.7 | 65.3 | 62.3% | |
Shares outstanding (eoy) | m | 267.03 | 127.28 | 209.8% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 11.3 | 4.9 | 231.6% | |
Avg P/E ratio | x | 8.7 | 37.1 | 23.4% | |
P/CF ratio (eoy) | x | 8.5 | 29.6 | 28.7% | |
Price / Book Value ratio | x | 1.3 | 3.9 | 33.5% | |
Dividend payout | % | 3.3 | 22.0 | 14.9% | |
Avg Mkt Cap | Rs m | 14,139 | 32,272 | 43.8% | |
No. of employees | `000 | NA | 1.1 | 0.0% | |
Total wages/salary | Rs m | 207 | 661 | 31.4% | |
Avg. sales/employee | Rs Th | NM | 6,132.2 | - | |
Avg. wages/employee | Rs Th | NM | 611.1 | - | |
Avg. net profit/employee | Rs Th | NM | 803.5 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 1,255 | 6,635 | 18.9% | |
Other income | Rs m | 370 | 242 | 152.8% | |
Total revenues | Rs m | 1,625 | 6,877 | 23.6% | |
Gross profit | Rs m | 111 | 1,604 | 6.9% | |
Depreciation | Rs m | 38 | 221 | 17.1% | |
Interest | Rs m | 2 | 38 | 4.5% | |
Profit before tax | Rs m | 442 | 1,587 | 27.8% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 1,212 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 24 | 718 | 3.3% | |
Profit after tax | Rs m | 1,630 | 869 | 187.5% | |
Gross profit margin | % | 8.9 | 24.2 | 36.6% | |
Effective tax rate | % | 5.4 | 45.2 | 12.0% | |
Net profit margin | % | 129.8 | 13.1 | 990.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 1,867 | 6,232 | 30.0% | |
Current liabilities | Rs m | 591 | 1,490 | 39.7% | |
Net working cap to sales | % | 101.6 | 71.5 | 142.2% | |
Current ratio | x | 3.2 | 4.2 | 75.5% | |
Inventory Days | Days | 94 | 86 | 109.1% | |
Debtors Days | Days | 74 | 83 | 89.0% | |
Net fixed assets | Rs m | 1,791 | 4,043 | 44.3% | |
Share capital | Rs m | 534 | 127 | 419.6% | |
"Free" reserves | Rs m | 10,324 | 8,183 | 126.2% | |
Net worth | Rs m | 10,858 | 8,310 | 130.7% | |
Long term debt | Rs m | 41 | 18 | 231.5% | |
Total assets | Rs m | 11,591 | 10,389 | 111.6% | |
Interest coverage | x | 260.9 | 43.1 | 605.2% | |
Debt to equity ratio | x | 0 | 0 | 177.1% | |
Sales to assets ratio | x | 0.1 | 0.6 | 17.0% | |
Return on assets | % | 14.1 | 8.7 | 161.2% | |
Return on equity | % | 15.0 | 10.5 | 143.5% | |
Return on capital | % | 15.2 | 19.5 | 77.8% | |
Exports to sales | % | 1.5 | 0 | - | |
Imports to sales | % | 21.0 | 0 | - | |
Exports (fob) | Rs m | 19 | NA | - | |
Imports (cif) | Rs m | 263 | NA | - | |
Fx inflow | Rs m | 19 | 5,622 | 0.3% | |
Fx outflow | Rs m | 264 | 1,799 | 14.7% | |
Net fx | Rs m | -244 | 3,822 | -6.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 236 | 356 | 66.3% | |
From Investments | Rs m | -224 | -279 | 80.4% | |
From Financial Activity | Rs m | -27 | -225 | 11.8% | |
Net Cashflow | Rs m | -15 | -148 | 10.0% |
Indian Promoters | % | 64.0 | 63.4 | 100.9% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.2 | 0.0 | - | |
FIIs | % | 9.7 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 26.1 | 36.5 | 71.5% | |
Shareholders | 54,701 | 37,287 | 146.7% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ALEMBIC With: PANACEA BIOTECH DIVIS LABORATORIES FULFORD INDIA NATCO PHARMA AJANTA PHARMA
Compare ALEMBIC With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets ended at record-high levels yesterday with Nifty ending above 14,600-mark.
For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.
For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.
For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.
More Views on NewsThe smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Our ace stock picker is ready to capitalise on a big growth opportunity.
More